Focus:
The widening commercial frontier for Gardasil 9 is a reflection of evolving vaccination objectives across the globe and presents an opportunity to decrease or potentially eliminate HPV-related cancers worldwide
GamaMabs Pharma has plans to initiate a Phase IIb or III metastatic colorectal cancer (mCRC) trial for murlentamab in 1H20, CEO Stéphane Degove revealed.
Genfit’s 2,000-patient Phase III RESOLVE-IT trial investigating elafibranor in nonalcoholic steatohepatitis is likely to close enrolment sometime in September
A novel blood test that is less intrusive and more accurate at detecting early brain changes has moved one step closer to clinical use
Rhythm Pharmaceuticals announced positive top line results this week from two pivotal Phase III trials evaluating setmelanotide in two rare forms of genetic obesity
Allakos Inc. announced strongly positive results this week from its pivotal Phase II ENIGMA trial testing AK002
Roche's Tecentriq met its co-primary endpoint in the Phase III IMvigor 130 trial, but it is too early to come to a final conclusion
The EU approval of two new methods of administration of GSK's Nucala will keep the biologic ahead of others, despite rising competition.
AI and machine learning can be utilised in the treatment of breast cancer through analysing molecular data and informing personalised medicine and treatment decisions.
Novartis experienced a major setback with failure of Entresto to achieve its primary endpoint to be used in the treatment of heart failure
